On June 8, 2021 Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") reported the presentation of new data in acute myeloid leukemia (AML) at the European Hematology Association (EHA) (Free EHA Whitepaper) virtual congress, taking place June 9-17 (Press release, Astellas, JUN 8, 2021, View Source [SID1234583695]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Eight Astellas-sponsored abstracts focused on patients with AML are being presented, comprising two oral presentations, four posters and two online-only abstract publications.
"We’re pleased to present new investigational research at EHA (Free EHA Whitepaper) 2021 that examines how patients and healthcare providers value different treatment approaches in AML," said Erhan Berrak, M.D., Vice President of Medical Affairs, Oncology, Astellas. "For example, one oral presentation sheds light on patients’ preferences for treatment, which may help to inform decisions of healthcare professionals when considering a plan for treatment after hematopoietic stem cell transplantation."
"Clinical trial results to be presented reflect our deep commitment to AML research, where we are investigating gilteritinib as monotherapy or in combination with other treatments, and across the range of patients with FLT3 mutation-positive AML, including patients whose AML is newly diagnosed or relapsed or refractory," said Andrew Krivoshik, M.D., Ph.D., Senior Vice President and Oncology Therapeutic Area Head, Astellas.
Oral Presentations
Oral presentations are available online from Friday, June 11 at 9 a.m. CEST, when all prerecorded presentations will be published on the virtual congress platform.
Title: Patient and Physician Preferences for Post–Hematopoietic Stem Cell Transplantation Maintenance Treatment of Acute Myeloid Leukemia (Abstract S313)
Presenting author: Manasee V. Shah, Astellas Pharma Inc., Northbrook, Ill., USA
Title: Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Updated Analyses of a Phase 1b Study (Supported by AbbVie, Astellas and Genentech) (Abstract S135)
Presenting author: Jessica K. Altman, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Ill., USA
E-Poster Presentations
E-poster presentations are available from Friday, June 11 at 9 a.m. CEST, when the e-posters are published on the virtual congress platform.
Title: Follow-up of Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia in the Phase 3 ADMIRAL Trial (Abstract EP438)
Presenting author: Mark J. Levis, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Md., USA
Title: Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib (Abstract EP448)
Presenting author: Alexander E. Perl, Abramson Comprehensive Cancer Center, University of Pennsylvania, Philadelphia, Pa., USA
Title: Outcomes in Gilteritinib-Treated FLT3-Mutated R/R AML Patients Who Underwent Transplantation (Abstract EP441)
Presenting author: Alexander E. Perl, Abramson Comprehensive Cancer Center, University of Pennsylvania, Philadelphia, Pa., USA
Title: A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results Update (Abstract EP437)
Presenting author: Keith W. Pratz, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Md., USA
Online-only abstract publications
Online-only abstracts are available via the virtual congress platform.
Title: Retrospective Assessment of Treatment Patterns and Resource Utilization for Patients Newly Diagnosed with Acute Myeloid Leukemia in Canada, UK, France, Germany, Italy, and Spain (Abstract PB1390)
Title: Frequency of FLT3-ITD and FLT3-TKD Mutations in Patients with Acute Myeloid Leukemia: A Systematic Literature Review and Meta-Analysis (Abstract PB1405)
The EHA (Free EHA Whitepaper) 2021 virtual congress abstracts are available in the EHA (Free EHA Whitepaper) Library.
About Acute Myeloid Leukemia (AML)
Acute myeloid leukemia (AML) is a type of cancer that affects the bone marrow and blood. It is deemed "acute," meaning that this type of leukemia can progress quickly.1 In the European Union, the incidence rate of AML is 3.7 per 100,000 per year, resulting in an estimated 16,800 individuals diagnosed.2
About Gilteritinib
Gilteritinib was discovered through a research collaboration with Kotobuki Pharmaceutical Co., Ltd., and Astellas has exclusive global rights to develop, manufacture and commercialize gilteritinib. Gilteritinib is available as XOSPATA in the U.S., Japan, China and selected European countries, among others, for the treatment of adult patients who have relapsed or refractory FLT3mut+ AML.3,4,5 Gilteritinib is an FMS-like tyrosine kinase 3 (FLT3) inhibitor with demonstrated activity against FLT3-ITD, a common driver mutation that presents with a high burden and poor prognosis, and FLT3-TKD mutations.6
European Union Important Safety Information
For important Safety Information for gilteritinib please see the full Summary of Product Characteristics at: View Source
United States Important Safety Information
For important Safety Information for gilteritinib please see Important Safety Information at: View Source